ASBPW
Aspire Biopharma Holdings, Inc.
Price Chart
Latest Quote
$0.02
+0.00 (+0.50%)
Current Price
| Previous Close | $0.02 |
| Open | $0.04 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 1,641 |
Stock Information
| Total Debt | $1.50M |
| Cash Equivalents | $5.86M |
| Revenue | $35K |
| Net Income | $-11.76M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Sales | $35K |
| Income | $-11.76M |
| Book/sh | $23.10 |
Financial Ratios
| Quick Ratio | 1.86 |
| Current Ratio | 2.26 |
| Debt/Eq | 38.76 |
Returns & Margins
| ROA | 119.60% |
| Gross Margin | 16.30% |
| Operating Margin | -5805.98% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.02 |
| SMA50 | $0.05 |
| RSI | nan |
| Shares Float | 1.20M |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| YTD | +0.00% |
| 10 Years | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.02 | 0 |
| 2026-06-11 | $0.02 | 0 |
| 2026-06-10 | $0.02 | 0 |
| 2026-06-09 | $0.02 | 0 |
| 2026-06-08 | $0.02 | 0 |
| 2026-06-05 | $0.02 | 0 |
| 2026-06-04 | $0.02 | 0 |
| 2026-06-03 | $0.02 | 0 |
| 2026-06-02 | $0.02 | 0 |
| 2026-06-01 | $0.02 | 0 |
| 2026-05-29 | $0.02 | 0 |
| 2026-05-28 | $0.02 | 0 |
| 2026-05-27 | $0.02 | 0 |
| 2026-05-26 | $0.02 | 0 |
| 2026-05-22 | $0.02 | 0 |
| 2026-05-21 | $0.02 | 0 |
| 2026-05-20 | $0.02 | 0 |
| 2026-05-19 | $0.02 | 0 |
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
đ° Latest News
Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)
InvestorsHub âĸ 2026-06-12T14:20:03Z
ASBP Stock Heads For Best Week In Over 2 Months â Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?
Stocktwits âĸ 2026-06-12T14:14:53Z
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program
Insider Monkey âĸ 2026-05-13T17:46:36Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-11-14T15:30:17ZAspire Biopharmaâs BUZZ BOMB Shows Promising Initial Feedback
Insider Monkey âĸ 2025-07-25T16:22:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,318 | $0 | $0 | $0 |
| Cost Of Revenue | $6,318 | $0 | $0 | $0 |
| Total Revenue | $6,202 | $0 | $0 | $0 |
| Operating Revenue | $6,202 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $8,531,275 | $97,988 | $8,966 | $0 |
| Total Expenses | $19,357,493 | $1,210,871 | $1,340,168 | $596,491 |
| Other Income Expense | $3,401,718 | $-9,105,853 | - | - |
| Other Non Operating Income Expenses | $3,860,889 | $-9,105,853 | - | - |
| Net Non Operating Interest Income Expense | $-8,531,275 | $-97,988 | $5,804,247 | $0 |
| Interest Expense Non Operating | $8,531,275 | $97,988 | $8,966 | $0 |
| Operating Expense | $19,351,175 | $1,210,871 | $1,340,168 | $596,491 |
| Selling And Marketing Expense | $789,829 | $126,094 | $39,644 | $45,483 |
| General And Administrative Expense | $17,637,432 | $940,421 | $1,340,168 | $375,692 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Interest Income | $-8,531,275 | $-97,988 | $5,804,247 | $0 |
| Normalized Income | $-24,021,677 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Income From Continuing And Discontinued Operation | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Income Common Stockholders | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Income | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Income Including Noncontrolling Interests | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Net Income Continuous Operations | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Pretax Income | $-24,480,848 | $-1,308,859 | $4,464,079 | $-596,491 |
| Special Income Charges | $-364,109 | $0 | - | - |
| Operating Income | $-19,351,291 | $-1,210,871 | $-1,340,168 | $-596,491 |
| Gross Profit | $-116 | $0 | $0 | $0 |
| Interest Income | - | $548,676 | $5,813,213 | - |
| Interest Income Non Operating | - | $548,676 | $5,813,213 | - |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,490,402 | $-1,210,871 | $4,473,045 | $-596,491 |
| Total Unusual Items | $-459,171 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-459,171 | $0 | - | - |
| EBITDA (Bullshit earnings) | $-15,949,573 | $-1,210,871 | $4,473,045 | $-596,491 |
| EBIT | $-15,949,573 | $-1,210,871 | $4,473,045 | $-596,491 |
| Diluted NI Availto Com Stockholders | $-24,480,848 | $-1,309,872 | $4,464,079 | $-597,117 |
| Tax Provision | $0 | $1,013 | $481 | $626 |
| Other Special Charges | $364,109 | - | - | - |
| Gain On Sale Of Security | $-95,062 | - | - | - |
| Research And Development | $923,914 | $144,356 | $72,050 | $175,316 |
| Selling General And Administration | $18,427,261 | $1,066,515 | $1,340,168 | $421,175 |
| Other Gand A | $17,637,432 | $940,421 | $1,340,168 | $375,692 |
| Reconciled Depreciation | - | $0 | $0 | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Total Assets | $1,312,166 | $147,989 | $46,174 | $22,538 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $1,312,166 | $147,989 | $46,174 | $22,538 |
| Other Current Assets | $55,102 | $144,356 | $35,000 | $22,500 |
| Prepaid Assets | $55,102 | $144,356 | $35,000 | $22,500 |
| Inventory | $253,160 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $1,003,904 | $3,633 | $11,174 | $38 |
| Cash And Cash Equivalents | $1,003,904 | $3,633 | $11,174 | $38 |
| Cash Financial | $1,003,904 | $3,633 | $11,174 | $38 |
| Receivables | - | $0 | $0 | $0 |
| Goodwill And Other Intangible Assets | - | - | $4,971,007 | $4,895,106 |
| Debt | ||||
| Net Debt | $4,171,350 | $1,263,199 | $349,462 | $27,929 |
| Total Debt | $5,175,254 | $1,266,832 | $360,636 | $27,967 |
| Current Debt And Capital Lease Obligation | $5,175,254 | $1,266,832 | $360,636 | $27,967 |
| Current Debt | $5,175,254 | $1,266,832 | $360,636 | $27,967 |
| Other Current Borrowings | $2,790,476 | $1,266,832 | $360,636 | $27,967 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,688,495 | $1,688,077 | $534,035 | $151,328 |
| Total Non Current Liabilities Net Minority Interest | $95,662 | $0 | $0 | $1 |
| Derivative Product Liabilities | $95,662 | $0 | - | - |
| Current Liabilities | $7,592,833 | $1,688,077 | $534,035 | $151,327 |
| Other Current Liabilities | $40,954 | $111,026 | $626 | $626 |
| Current Notes Payable | $2,384,778 | $1,266,832 | - | - |
| Payables And Accrued Expenses | $2,376,625 | $310,219 | $172,773 | $122,734 |
| Payables | $1,368,056 | $310,219 | $172,773 | $122,734 |
| Accounts Payable | $1,014,377 | $310,219 | $172,773 | $122,734 |
| Other Non Current Liabilities | - | - | $3,852,552 | $3,852,553 |
| Equity | ||||
| Common Stock Equity | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Total Equity Gross Minority Interest | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Stockholders Equity | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Retained Earnings | $-27,258,081 | $-2,777,233 | $-1,467,361 | $-1,108,290 |
| Preferred Stock Equity | - | $32 | - | - |
| Other | ||||
| Ordinary Shares Number | $117,780 | $38,339 | $38,339 | $38,339 |
| Share Issued | $117,780 | $38,339 | $38,339 | $38,339 |
| Tangible Book Value | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Invested Capital | $-1,201,075 | $-273,256 | $-127,225 | $-100,823 |
| Working Capital | $-6,280,667 | $-1,540,088 | $-487,861 | $-128,789 |
| Total Capitalization | $-6,376,329 | $-1,540,088 | $-487,861 | $-128,790 |
| Additional Paid In Capital | $20,881,399 | $1,237,076 | $957,500 | $758,000 |
| Capital Stock | $353 | $69 | $22,000 | $221,500 |
| Common Stock | $353 | $69 | $22,000 | $221,500 |
| Preferred Stock | $0 | $0 | $0 | - |
| Current Accrued Expenses | $1,008,569 | $0 | - | - |
| Dueto Related Parties Current | $353,679 | $0 | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,923,488 | $-265,186 | $11,136 | $-5,038,011 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,923,488 | $-265,186 | $11,136 | $-142,905 |
| Cash Flow From Continuing Operating Activities | $-4,923,488 | $-265,186 | $11,136 | $-142,905 |
| Operating Gains Losses | $-3,401,718 | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $0 | $-4,895,106 |
| Capital Expenditure | - | - | $-75,902 | $-4,895,106 |
| Cash Flow From Continuing Investing Activities | - | - | $-75,902 | $-4,895,106 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $265,827 | $257,645 | $0 | $1,000,000 |
| Financing Cash Flow | $5,923,759 | $257,645 | $0 | $4,852,552 |
| Cash Flow From Continuing Financing Activities | $5,923,759 | $257,645 | $0 | $4,852,552 |
| Net Other Financing Charges | $-907,499 | - | - | $3,852,552 |
| Net Common Stock Issuance | $265,827 | $257,645 | $0 | $1,000,000 |
| Common Stock Issuance | $265,827 | $257,645 | $0 | $1,000,000 |
| Other | ||||
| Repayment Of Debt | $-3,734,569 | $0 | - | - |
| Issuance Of Debt | $10,300,000 | $0 | - | - |
| Interest Paid Supplemental Data | $44,388 | $0 | $0 | - |
| End Cash Position | $1,003,904 | $3,633 | $11,174 | $38 |
| Beginning Cash Position | $3,633 | $11,174 | $38 | $185,496 |
| Changes In Cash | $1,000,271 | $-7,541 | $11,136 | $-185,458 |
| Net Issuance Payments Of Debt | $6,565,431 | $0 | - | - |
| Net Short Term Debt Issuance | $6,565,431 | $0 | - | - |
| Short Term Debt Payments | $-3,734,569 | $0 | - | - |
| Short Term Debt Issuance | $10,300,000 | $0 | - | - |
| Change In Working Capital | $533,380 | $1,044,686 | $370,206 | $454,212 |
| Change In Other Current Liabilities | $-111,026 | $906,196 | $332,668 | $-68,576 |
| Change In Payables And Accrued Expense | $723,312 | $247,846 | $50,038 | $145,288 |
| Change In Accrued Expense | $1,047,088 | $0 | $75,902 | $42,554 |
| Change In Payable | $-323,776 | $247,846 | $50,038 | $102,734 |
| Change In Account Payable | $-323,776 | $247,846 | $50,038 | $102,734 |
| Change In Prepaid Assets | $174,254 | $-109,356 | $-12,500 | $-22,500 |
| Change In Inventory | $-253,160 | $0 | - | - |
| Other Non Cash Items | $8,294,448 | - | - | - |
| Stock Based Compensation | $14,131,250 | $0 | - | - |
| Gain Loss On Investment Securities | $-3,765,827 | - | - | - |
| Net Income From Continuing Operations | $-24,480,848 | $-1,309,872 | $-359,070 | $-597,117 |
| Income Tax Paid Supplemental Data | - | $1,013 | $0 | - |
| Change In Receivables | - | $0 | $0 | $400,000 |
| Depreciation Amortization Depletion | - | $0 | $0 | $0 |
| Depreciation And Amortization | - | $0 | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $-75,902 | $-4,895,106 |
Fetched: 2026-06-17